Dark

ACRS
Aclaris Therapeutics, Inc.
stock NASDAQ

At Close

Jul 28, 2026 3:59:58 PM EDT

5.32USD-0.931%(-0.05)1,552,975

4.38Bid 6.26Ask 1.88Spread

Pre-market

0.00USD-100.000%(-5.23)0

After-hours

Jul 27, 2026 4:32:30 PM EDT

5.36USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 12, 2022

02:57PM EST Mid-Afternoon Market Update: Nasdaq Rises 50 Points; Jefferies Shares Drop Benzinga

12:32PM EST Mid-Day Market Update: Crude Oil Rises 2%; Philips Shares Plummet Benzinga

08:30AM EST The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award Benzinga

Jan 11, 2022

04:01PM EST Aclaris Therapeutics Offers R&D Update Benzinga

04:01PM EST Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its clinical programs and on its research and development (R&D) operations. GlobeNewswire Inc

Dec 27, 2021

07:00AM EST Aclaris Therapeutics to Participate in the H.C. Wainwright GlobeNewswire Inc

Dec 3, 2021

07:01AM EST Aclaris Therapeutics Reports Publication Of Preclinical Research Of Zunsemetinib In Pancreatic Cancer In Science Translational Medicine Benzinga

07:00AM EST Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the publication of preclinical research of zunsemetinib in pancreatic cancer in the peer-reviewed journal Science Translational Medicine, on December 1, 2021. GlobeNewswire Inc

Nov 18, 2021

04:01PM EST Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021 GlobeNewswire Inc

Nov 3, 2021

07:00AM EDT Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor conferences: GlobeNewswire Inc

Nov 2, 2021

11:51AM EDT Looking Into Aclaris Therapeutics's Return On Capital Employed Benzinga

10:50AM EDT Aclaris Therapeutics Q3 EPS $(0.35) Down From $(0.25) YoY, Sales $1.66M Up From $1.45M YoY Benzinga

07:00AM EDT -- Investigational New Drug Application for ATI-2138 for the Treatment of Psoriasis Submitted in October 2021 -- Planning to Initiate Phase 2b Trial of Zunsemetinib (ATI-450) in Moderate to Severe Rheumatoid Arthritis in the Fourth Quarter of 2021 GlobeNewswire Inc

Sep 20, 2021

08:00AM EDT Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of securities of Aclaris Therapeutics, Inc. (NASDAQ: ACRS): GlobeNewswire Inc

Sep 3, 2021

07:31AM EDT The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself Benzinga

Aug 27, 2021

05:13PM EDT Looking into Aclaris Therapeutics's Return on Capital Employed Benzinga

04:01PM EDT Aclaris Therapeutics Announces Proposed Settlement And Settlement Hearing Of Stockholder Derivative Action Benzinga

04:01PM EDT Aclaris Therapeutics Announces Proposed Settlement and Settlement GlobeNewswire Inc

Aug 26, 2021

04:01PM EDT Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor conferences: GlobeNewswire Inc

Aug 5, 2021

07:44AM EDT Aclaris Therapeutics Q2 EPS $(0.34) Down From $(0.28) YoY, Sales $1.82M Down From $2.05M YoY Benzinga

07:00AM EDT Aclaris Therapeutics Reports Second Quarter 2021 Financial Results GlobeNewswire Inc

Jul 8, 2021

07:02AM EDT Aclaris Therapeutics to Participate in the William Blair Biotech GlobeNewswire Inc

Jun 16, 2021

07:51AM EDT HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Raises Price Target to $50 Benzinga

Jun 15, 2021

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 Benzinga

06:25AM EDT Piper Sandler Initiates Coverage On Aclaris Therapeutics with Overweight Rating, Announces Price Target of $30 Benzinga

Jun 14, 2021

07:41AM EDT Aclaris Therapeutics Prices Public Offering Of 7.04 Mln Shares At $17.75 Per Share RTTNews

Jun 9, 2021

07:55PM EDT Aclaris Announces Pricing of Public Offering of Common Stock GlobeNewswire Inc

09:14AM EDT The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US Benzinga

Jun 8, 2021

04:15PM EDT Aclaris Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

04:15PM EDT Aclaris Reports $75M Common Stock Offering Benzinga

02:38PM EDT Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Aclaris Therapeutics Shares Plunge Benzinga

12:09PM EDT Mid-Day Market Update: Coupa Software Drops After Q1 Results; NextDecade Shares Jump Benzinga

07:46AM EDT Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure Benzinga

07:13AM EDT Aclaris Therapeutics Announces Positive Preliminary Topline Data From Phase 2a Trial Of ATI-1777 For Atopic Dermatitis RTTNews

07:09AM EDT Aclaris Therapeutics Announces Phase 2a Trial Results Showing ATI-1777 Achieved Statistically Significant Result In the Primary Efficacy Endpoint At Week 4 Benzinga

07:00AM EDT -- ATI-1777 Achieved Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 -- Minimal Systemic Exposure Supports Soft Topical JAK Inhibitor Approach -- ATI-1777 was Generally Well Tolerated -- Data Support Progression to Phase 2b -- Management to Host Conference Call at 8:00 AM ET Today GlobeNewswire Inc

May 20, 2021

04:22PM EDT Aclaris Therapeutics 8-K Shows Co. Entered Sales Deal With SVB Leerink, Cantor Fitzgerald For Sale Of $150M In Common Stock Benzinga

May 17, 2021

07:00AM EDT Aclaris Therapeutics to Participate in the Jefferies Virtual GlobeNewswire Inc

May 7, 2021

07:05AM EDT Aclaris Therapeutics Q1 EPS $(0.57) Down From $(0.37) YoY, Sales $1.78B Up From $1.41M YoY Benzinga

07:00AM EDT Aclaris Therapeutics Reports First Quarter 2021 Financial Results GlobeNewswire Inc

Apr 21, 2021

01:59PM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2021 Benzinga

06:28AM EDT HC Wainwright & Co. Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $40 Benzinga

Apr 8, 2021

08:14AM EDT The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data Benzinga

Apr 6, 2021

08:05AM EDT The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout Benzinga

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

Mar 16, 2021

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

Mar 15, 2021

07:18AM EDT Aclaris Therapeutics Completes Enrollment In Phase 2a Clinical Trial Of ATI-1777 RTTNews

07:03AM EDT Aclaris Therapeutics Completes Enrollment In Phase 2a Clinical Trial Of ATI-1777 For Moderate To Severe Atopic Dermatitis; Data Expected Mid-Year 2021 Benzinga

07:00AM EDT Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical GlobeNewswire Inc

Mar 4, 2021

07:47AM EST 10 Biggest Price Target Changes For Thursday Benzinga

06:17AM EST SVB Leerink Maintains Outperform on Aclaris Therapeutics, Raises Price Target to $26 Benzinga

Feb 25, 2021

07:06AM EST Aclaris Therapeutics Q4 EPS $(0.30) Up From $(0.45) YoY, Sales $1.58M Up From $1.09M YoY Benzinga

07:00AM EST -- Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021 -- ATI-450 Data Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid Arthritis -- Public Offering of $103.5M in January 2021 Strengthens Balance Sheet GlobeNewswire Inc

Feb 22, 2021

07:00AM EST Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will present a company overview at the following upcoming virtual investor conferences: GlobeNewswire Inc

Feb 10, 2021

07:00AM EST Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink GlobeNewswire Inc

Jan 25, 2021

02:41PM EST Gaining Ground After A Tough Couple Of Weeks Benzinga

Jan 22, 2021

09:59AM EST Watching Aclaris Shares Following Jan. 21-Dated AccessData.FDA.gov Listing For Orphan Drug Designation Of Co.'s Cryopyrin-Associated Periodic Syndrome Treatment Benzinga

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 20, 2021

09:56AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

08:46AM EST Aclaris Announces Pricing Of Public Offering Of 5.48M Shares Of Common Stock At $17.50/Share Benzinga

08:45AM EST Aclaris Announces Pricing of Public Offering of Common Stock GlobeNewswire Inc

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

04:46AM EST SVB Leerink Maintains Outperform on Aclaris Therapeutics, Raises Price Target to $21 Benzinga

Jan 19, 2021

04:01PM EST Aclaris Announces Proposed Public Offering of Common Stock; No Terms Disclosed Benzinga

04:01PM EST Aclaris Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

02:58PM EST Mid-Afternoon Market Update: Nasdaq Surges 1.5%; Aclaris Therapeutics Shares Spike Higher Benzinga

12:16PM EST Mid-Day Market Update: Crude Oil Rises Over 1%; ProPhase Labs Shares Plummet Benzinga

10:19AM EST Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Earnings Top Views Benzinga

10:11AM EST Shares of Aclaris Therapeutics, Inc. (ACRS) are surging over 160% after the clinical-stage biopharmaceutical company announced positive preliminary topline data from mid-stage trial of rheumatoid arthritis treatment. RTTNews

07:09AM EST Aclaris Announces Positive Preliminary Data From 12-Week Phase 2a Trial Of Oral ATI-450 For Rheumatoid Arthritis RTTNews

07:06AM EST Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis Benzinga

07:00AM EST -- Durable Clinical Activity over 12 Weeks was Demonstrated -- Data Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid Arthritis -- ATI-450, an Investigational Oral MK2 Inhibitor, was Generally Well Tolerated -- Data Support Progression to Phase 2b -- Management to Host Conference Call at 8:00 AM ET Today GlobeNewswire Inc

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 17, 2020

08:10AM EST The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga

Dec 16, 2020

01:00PM EST Mid-Morning Market Update: Markets Mostly Flat; Aphria and Tilray To Merge Benzinga

10:27AM EST Mid-Morning Market Update: Markets Edge Lower; Aphria and Tilray To Merge Benzinga

Dec 15, 2020

07:00AM EST -- New Scientific Advisory Board of Immuno-Inflammatory Experts -- Preliminary Topline Data for the ATI-450-RA-201 Trial Expected in January 2021 GlobeNewswire Inc

Nov 16, 2020

04:01PM EST Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual GlobeNewswire Inc

Nov 4, 2020

07:05AM EST Aclaris Therapeutics Q3 EPS $(0.25) Up From $(0.56) YoY, Sales $1.45M Up From $983.00K YoY Benzinga

07:00AM EST -- First Subject Dosed in Phase 2a Trial of ATI-1777, an Investigational Topical Soft JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis -- Initiated Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, for the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS) GlobeNewswire Inc

Oct 20, 2020

07:06AM EDT Aclaris Therapeutics Announces First Patient Dosed In Phase 2a Clinical Trial Of ATI-1777, An Investigational Topical Soft JAK 1/3 Inhibitor, For The Treatment Of Moderate To Severe Atopic Dermatitis Benzinga

07:00AM EDT Aclaris Therapeutics Announces First Patient Dosed in Phase 2a GlobeNewswire Inc

Sep 1, 2020

04:01PM EDT Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management willparticipate in the following upcoming virtual investor conferences: GlobeNewswire Inc

Aug 7, 2020

07:22AM EDT Aclaris Therapeutics Q2 EPS $(0.28); Sales $2.04M Benzinga

07:00AM EDT Aclaris Therapeutics Reports Second Quarter 2020 Financial Results GlobeNewswire Inc

Jul 20, 2020

11:16AM EDT Shares of Aclaris Therapeutics, Inc. (ACRS) are currently gaining nearly 40% on Monday morning despite no stock-specific news. Pharma companies are performing better on Monday as investors are more interested in the industry on the back of positive reports of COVID-19 vaccine. RTTNews